Premium
CAVEAT mTOR: You’ve heard about the benefits of using mTOR inhibitors, here are some of the risks
Author(s) -
Eisen Howard J.
Publication year - 2021
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.16225
Subject(s) - medicine , pi3k/akt/mtor pathway , discovery and development of mtor inhibitors , intensive care medicine , genetics , signal transduction , biology
Eisen reviews Asleh et al.'s article ( page 626) that shows that the development of significant proteinuria after conversion to mTOR‐ based immunosuppression is a harbinger of poor outcomes for cardiac transplant recipients.